Literature DB >> 32638218

Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats.

Maricarmen Hernández-Rodríguez1,2, Ivonne Maciel Arciniega-Martínez3, Iohanan Daniel García-Marín1,2, José Correa-Basurto4, Martha Cecilia Rosales-Hernández5.   

Abstract

The increase of amyloid beta (Aβ) release and hyperphosphorylation of Tau protein represents the main events related to Alzheimer's disease (AD). Furthermore, the sporadic type represents the most common form of AD. Therefore, the establishment of a non-transgenic animal model that resembles the characteristics of the disease is of particular importance. Scopolamine has been linked to increases in both Aβ production and oxidative stress in rat and mice brains. Thus, the purpose of the present work was to identify changes in biomarkers that are related to AD after chronic administration of scopolamine (2 mg/kg i.p., during 6 and 12 weeks) to male Wistar rats. The results showed increased Aβ deposition at rat hippocampus which could be due to an increase of β-site amyloid-β-protein precursor cleaving enzyme 1 (BACE1) expression and activity. These findings could be related to the increase of glycogen synthase kinase 3 phosphorylated (GSK3βP9) expression. Finally, the establishment of a state of oxidative stress in groups treated with scopolamine was demonstrated by an increase in free radical content and MDA levels. The present study facilitates our understanding of the changes that occur in biomolecules related to AD in Wistar rats after the chronic administration of scopolamine.

Entities:  

Keywords:  Alzheimer’ disease; Beta amyloid; Oxidative stress; Scopolamine

Year:  2020        PMID: 32638218     DOI: 10.1007/s12035-020-02009-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  41 in total

Review 1.  The molecular pathology of Alzheimer's disease.

Authors:  Charles R Harrington
Journal:  Neuroimaging Clin N Am       Date:  2012-02       Impact factor: 2.264

Review 2.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 3.  A brief overview of amyloids and Alzheimer's disease.

Authors:  Sian-Yang Ow; Dave E Dunstan
Journal:  Protein Sci       Date:  2014-07-30       Impact factor: 6.725

Review 4.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

Review 5.  The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics.

Authors:  Kevin Mullane; Michael Williams
Journal:  Curr Opin Pharmacol       Date:  2019-02-19       Impact factor: 5.547

Review 6.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 7.  The secretases: enzymes with therapeutic potential in Alzheimer disease.

Authors:  Bart De Strooper; Robert Vassar; Todd Golde
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 9.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

Authors:  Erika N Cline; Maíra Assunção Bicca; Kirsten L Viola; William L Klein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease.

Authors:  Balmiki Ray; Bryan Maloney; Kumar Sambamurti; Hanuma K Karnati; Peter T Nelson; Nigel H Greig; Debomoy K Lahiri
Journal:  Transl Psychiatry       Date:  2020-02-03       Impact factor: 6.222

View more
  1 in total

1.  Tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl)carbamate Has Moderated Protective Activity in Astrocytes Stimulated with Amyloid Beta 1-42 and in a Scopolamine Model.

Authors:  Raúl Horacio Camarillo-López; Maricarmen Hernández Rodríguez; Mónica Adriana Torres-Ramos; Ivonne Maciel Arciniega-Martínez; Iohanan Daniel García-Marín; José Correa Basurto; Juan Vicente Méndez Méndez; Martha Cecilia Rosales-Hernández
Journal:  Molecules       Date:  2020-10-29       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.